15,998
回編集
「テスト」の版間の差分
細
編集の要約なし
細編集の要約なし |
細編集の要約なし |
||
| 4行目: | 4行目: | ||
| Taltirelin Hydrate || [https://www.clinicaltrials.gov/ct2/show/NCT04107740 NCT04107740] || 2019- || 韓国 || SCD全般 || 4 || 現在進行中 | | Taltirelin Hydrate || [https://www.clinicaltrials.gov/ct2/show/NCT04107740 NCT04107740] || 2019- || 韓国 || SCD全般 || 4 || 現在進行中 | ||
|- | |- | ||
| KPS-0373(Rovatirelin) || [https://www.clinicaltrials.gov/ct2/show/NCT01970098 NCT01970098] || 2013-2015 || 日本 || 軽度～中等度のSCD || 3 || 部分的に有効 | | KPS-0373(Rovatirelin) || [https://www.clinicaltrials.gov/ct2/show/NCT01970098 NCT01970098] || 2013-2015 || 日本 || 軽度～中等度のSCD || 3 || [https://jnnp.bmj.com/content/91/3/254 部分的に有効] | ||
|- | |- | ||
| Riluzole || [https://www.clinicaltrials.gov/ct2/show/NCT03347344?cond=Spinocerebellar+Degeneration&draw=3&rank=11 NCT03347344] || 2018-2019 || フランス || SCA2 || 3 || 不明 | | Riluzole || [https://www.clinicaltrials.gov/ct2/show/NCT03347344?cond=Spinocerebellar+Degeneration&draw=3&rank=11 NCT03347344] || 2018-2019 || フランス || SCA2 || 3 || 不明 | ||
| 16行目: | 16行目: | ||
| Oral Trehalose || [https://www.clinicaltrials.gov/ct2/show/NCT04399265 NCT04399265] || 2020ー- || マレーシア || Genetically confirmed SCA 3 || Not Applicable || 進行中 | | Oral Trehalose || [https://www.clinicaltrials.gov/ct2/show/NCT04399265 NCT04399265] || 2020ー- || マレーシア || Genetically confirmed SCA 3 || Not Applicable || 進行中 | ||
|- | |- | ||
| Varenicline (Chantix®) || [https://www.clinicaltrials.gov/ct2/show/NCT00992771 NCT00992771] || 2009－2012 || 米国 || SCA3 || 2 || 有効 | | Varenicline (Chantix®) || [https://www.clinicaltrials.gov/ct2/show/NCT00992771 NCT00992771] || 2009－2012 || 米国 || SCA3 || 2 || [https://n.neurology.org/content/78/8/545.long 有効] | ||
|- | |- | ||
| Umbilical Cord Mesenchymal Stem Cells || [https://www.clinicaltrials.gov/ct2/show/NCT03378414 NCT03378414] || 2017－ || 中国 || SCA1,2,4,6 || 2 || 詳細不明 | | Umbilical Cord Mesenchymal Stem Cells || [https://www.clinicaltrials.gov/ct2/show/NCT03378414 NCT03378414] || 2017－ || 中国 || SCA1,2,4,6 || 2 || 詳細不明 | ||
| 28行目: | 28行目: | ||
| CAD-1883 || [https://www.clinicaltrials.gov/ct2/show/NCT04301284 NCT04301284] || 2020－ || 米国 || SCA1,2,3,6,7,10,17 || 2 || 延期(COVID-19のため | | CAD-1883 || [https://www.clinicaltrials.gov/ct2/show/NCT04301284 NCT04301284] || 2020－ || 米国 || SCA1,2,3,6,7,10,17 || 2 || 延期(COVID-19のため | ||
|- | |- | ||
| Docosahexaenoic Acid (DHA) || [https://www.clinicaltrials.gov/ct2/show/NCT03109626 NCT03109626] || 2015－2018 || イタリア || SCA38 || Not Applicable || 有効 | | Docosahexaenoic Acid (DHA) || [https://www.clinicaltrials.gov/ct2/show/NCT03109626 NCT03109626] || 2015－2018 || イタリア || SCA38 || Not Applicable || [https://onlinelibrary.wiley.com/doi/full/10.1002/ana.25059 有効] | ||
|- | |- | ||
| Stemchymal® || [https://www.clinicaltrials.gov/ct2/show/NCT02540655 NCT02540655] || 2015－ || 台湾 || SCA2,3 || 2 || 不明 | | Stemchymal® || [https://www.clinicaltrials.gov/ct2/show/NCT02540655 NCT02540655] || 2015－ || 台湾 || SCA2,3 || 2 || 不明 | ||
| 62行目: | 62行目: | ||
| Methylprednisolone || [https://www.clinicaltrials.gov/ct2/show/NCT02424435 NCT02424435] || 2015-2020 || 米国 || Friedreich Ataxia || 1 || リクルート終了 | | Methylprednisolone || [https://www.clinicaltrials.gov/ct2/show/NCT02424435 NCT02424435] || 2015-2020 || 米国 || Friedreich Ataxia || 1 || リクルート終了 | ||
|- | |- | ||
| EPI-743(alpha-tocotrienol quinone) || [https://clinicaltrials.gov/ct2/show/NCT01962363 NCT01962363] || 2013-2016 || 米国 || Friedreich's Ataxia with Point Mutations || 2 || 効果あり | | EPI-743(alpha-tocotrienol quinone) || [https://clinicaltrials.gov/ct2/show/NCT01962363 NCT01962363] || 2013-2016 || 米国 || Friedreich's Ataxia with Point Mutations || 2 || [https://n.neurology.org/content/86/16_Supplement/P5.388 効果あり] | ||
|- | |- | ||
| Omaveloxolone || [https://clinicaltrials.gov/ct2/show/NCT02255435 NCT02255435] || 2014- || 米国 || Friedreich Ataxia || 2 || リクルート停止 | | Omaveloxolone || [https://clinicaltrials.gov/ct2/show/NCT02255435 NCT02255435] || 2014- || 米国 || Friedreich Ataxia || 2 || リクルート停止 | ||
| 78行目: | 78行目: | ||
| Idebenone || [https://clinicaltrials.gov/ct2/show/NCT01303406 NCT01303406] || 2011-2016 || EU || Friedreich Ataxia || 3 || 有効性なし | | Idebenone || [https://clinicaltrials.gov/ct2/show/NCT01303406 NCT01303406] || 2011-2016 || EU || Friedreich Ataxia || 3 || 有効性なし | ||
|- | |- | ||
| A0001(alpha-tocopherolquinone) || [https://clinicaltrials.gov/ct2/show/NCT01035671 NCT01035671] || 2009-2011 || 米国 || Friedreich Ataxia || 2 || 容量依存性にFRDA評価スケール改善 | | A0001(alpha-tocopherolquinone) || [https://clinicaltrials.gov/ct2/show/NCT01035671 NCT01035671] || 2009-2011 || 米国 || Friedreich Ataxia || 2 || [https://onlinelibrary.wiley.com/doi/full/10.1002/mds.25058 容量依存性にFRDA評価スケール改善] | ||
|- | |- | ||
| Erythropoietin || [https://clinicaltrials.gov/ct2/show/NCT01016366 NCT01016366] || 2009-2016 || EU || Friedreich Ataxia || 2 || 有効性なし | | Erythropoietin || [https://clinicaltrials.gov/ct2/show/NCT01016366 NCT01016366] || 2009-2016 || EU || Friedreich Ataxia || 2 || 有効性なし | ||
| 84行目: | 84行目: | ||
| idebenone || [https://clinicaltrials.gov/ct2/show/NCT00993967 NCT00993967] || 2009-2016 || EU || Friedreich Ataxia || 3 || 認容性を副作用の確認 | | idebenone || [https://clinicaltrials.gov/ct2/show/NCT00993967 NCT00993967] || 2009-2016 || EU || Friedreich Ataxia || 3 || 認容性を副作用の確認 | ||
|- | |- | ||
| deferiprone || [https://clinicaltrials.gov/ct2/show/NCT00530127 NCT00530127] || 2007-2009 || EU || Friedreich Ataxia || 1,2 || 非重症例で進行抑制の可能性(+) | | deferiprone || [https://clinicaltrials.gov/ct2/show/NCT00530127 NCT00530127] || 2007-2009 || EU || Friedreich Ataxia || 1,2 || [https://onlinelibrary.wiley.com/doi/full/10.1002/ana.24248 非重症例で進行抑制の可能性(+)] | ||
|- | |- | ||
| EGb 761 || [https://clinicaltrials.gov/ct2/show/NCT00824512 NCT00824512] || 209-2013 || フランス || Friedreich Ataxia || 2 || 有効性なし | | EGb 761 || [https://clinicaltrials.gov/ct2/show/NCT00824512 NCT00824512] || 209-2013 || フランス || Friedreich Ataxia || 2 || 有効性なし | ||
| 102行目: | 102行目: | ||
| Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate || [https://clinicaltrials.gov/ct2/show/NCT01052623 NCT01052623] || 2010-2011 || ドイツ || Ataxia Telangiectasia || 4 || 結果？ | | Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate || [https://clinicaltrials.gov/ct2/show/NCT01052623 NCT01052623] || 2010-2011 || ドイツ || Ataxia Telangiectasia || 4 || 結果？ | ||
|- | |- | ||
| amantadine sulphate || [https://clinicaltrials.gov/ct2/show/NCT00950196 NCT00950196] || 2009-2011 || イスラエル || Ataxia Telangiectasia || 4 || 運動症状を改善 | | amantadine sulphate || [https://clinicaltrials.gov/ct2/show/NCT00950196 NCT00950196] || 2009-2011 || イスラエル || Ataxia Telangiectasia || 4 || [https://journals.sagepub.com/doi/10.1177/0883073812441999 運動症状を改善] | ||
|- | |- | ||
| Baclofen || [https://clinicaltrials.gov/ct2/show/NCT00640003 NCT00640003] || 2008-2011 || 米国 || Ataxia Telangiectasia || 1 || 結果？ | | Baclofen || [https://clinicaltrials.gov/ct2/show/NCT00640003 NCT00640003] || 2008-2011 || 米国 || Ataxia Telangiectasia || 1 || 結果？ | ||
|} | |} | ||